Loading…

Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients – Longterm follow-up

Abstract Aims To evaluate possible differences in effect on recurrence-free survival (RFS) and overall survival (OS) in node positive postmenopausal breast cancer patients receiving Tamoxifen or cyclic Tam and Megestrol acetate as adjuvant treatment. Methods Between 1989 and 1994, 489 patients with...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2008-01, Vol.34 (1), p.6-12
Main Authors: Fjøsne, H.E, Jacobsen, A.-B, Lundgren, S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims To evaluate possible differences in effect on recurrence-free survival (RFS) and overall survival (OS) in node positive postmenopausal breast cancer patients receiving Tamoxifen or cyclic Tam and Megestrol acetate as adjuvant treatment. Methods Between 1989 and 1994, 489 patients with pT1–2 pN+ hormone receptor positive or unknown tumours were included in a randomized national multicenter study to receive either Tam alone or cyclic Tam (8 weeks) and MA (8 weeks) for 2 years. Final follow-up was completed as of June 2002. Time from start of treatment to first recurrence and novel primary breast tumour, overall survival and cancer specific survival were estimated. Results No differences in RFS, OS or cancer specific survival were observed between the two treatment groups. Conclusions Adjuvant treatment used as standard Tam alone, compared to Tam and MA, as employed in this group of patients gave similar outcomes. Side effects that led to cessation of study medication were observed in both arms.
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2007.07.002